BACKGROUND: Directly observed therapy (DOT) programs for HIV treatment have demonstrated feasibility, acceptability, and improved viral suppression, but few have been rigorously tested. We describe a randomized controlled trial testing the efficacy of an antiretroviral DOT program in methadone maintenance clinics. Our objective was to determine if DOT is more efficacious than self-administered antiretroviral therapy for reducing HIV viral load, improving adherence, and reducing drug resistance among opioid dependent drug users receiving methadone treatment. METHODS: Participants were randomized to treatment as usual (TAU) or antiretroviral DOT for the 24-week intervention. TAU participants received standard adherence counseling, and DOT participants received standard adherence counseling plus directly observed antiretroviral therapy, which was delivered at the same time as they received daily methadone. Assessments occurred at baseline, weekly for 8 weeks, and then monthly for 4 months. Our primary outcomes were between-group changes from baseline to the end of the intervention in: HIV viral load, antiretroviral adherence, and number of viral mutations. RESULTS:Between June 2004 and August 2007, we screened 3231 methadone-maintained patients and enrolled 77; 39 participants were randomized to DOT and 38 to TAU. 65 completed the 24-week intervention. CONCLUSIONS: Our trial will allow rigorous evaluation of the efficacy of directly observed antiretroviral therapy delivered in methadone clinics for improving adherence and clinical outcomes. This detailed description of trial methodology can serve as a template for the development of future DOT programs and can guide protocols for studies among HIV-infected drug users receiving methadone for opioid dependence.
RCT Entities:
BACKGROUND: Directly observed therapy (DOT) programs for HIV treatment have demonstrated feasibility, acceptability, and improved viral suppression, but few have been rigorously tested. We describe a randomized controlled trial testing the efficacy of an antiretroviral DOT program in methadone maintenance clinics. Our objective was to determine if DOT is more efficacious than self-administered antiretroviral therapy for reducing HIV viral load, improving adherence, and reducing drug resistance among opioid dependent drug users receiving methadone treatment. METHODS:Participants were randomized to treatment as usual (TAU) or antiretroviral DOT for the 24-week intervention. TAU participants received standard adherence counseling, and DOT participants received standard adherence counseling plus directly observed antiretroviral therapy, which was delivered at the same time as they received daily methadone. Assessments occurred at baseline, weekly for 8 weeks, and then monthly for 4 months. Our primary outcomes were between-group changes from baseline to the end of the intervention in: HIV viral load, antiretroviral adherence, and number of viral mutations. RESULTS: Between June 2004 and August 2007, we screened 3231 methadone-maintained patients and enrolled 77; 39 participants were randomized to DOT and 38 to TAU. 65 completed the 24-week intervention. CONCLUSIONS: Our trial will allow rigorous evaluation of the efficacy of directly observed antiretroviral therapy delivered in methadone clinics for improving adherence and clinical outcomes. This detailed description of trial methodology can serve as a template for the development of future DOT programs and can guide protocols for studies among HIV-infected drug users receiving methadone for opioid dependence.
Authors: Andrea A Howard; Julia H Arnsten; Yungtai Lo; David Vlahov; Josiah D Rich; Paula Schuman; Valerie E Stone; Dawn K Smith; Ellie E Schoenbaum Journal: AIDS Date: 2002-11-08 Impact factor: 4.177
Authors: Karina M Berg; Penelope A Demas; Andrea A Howard; Ellie E Schoenbaum; Marc N Gourevitch; Julia H Arnsten Journal: J Gen Intern Med Date: 2004-11 Impact factor: 5.128
Authors: Frederick L Altice; Jo Anne Mezger; John Hodges; Robert D Bruce; Adrian Marinovich; Mary Walton; Sandra A Springer; Gerald H Friedland Journal: Clin Infect Dis Date: 2004-06-01 Impact factor: 9.079
Authors: S E Weis; P C Slocum; F X Blais; B King; M Nunn; G B Matney; E Gomez; B H Foresman Journal: N Engl J Med Date: 1994-04-28 Impact factor: 91.245
Authors: James C M Brust; Alain H Litwin; Karina M Berg; Xuan Li; Moonseong Heo; Julia H Arnsten Journal: AIDS Res Hum Retroviruses Date: 2010-11-23 Impact factor: 2.205
Authors: Sasha Uhlmann; M-J Milloy; Thomas Kerr; Ruth Zhang; Silvia Guillemi; David Marsh; Robert S Hogg; Julio S G Montaner; Evan Wood Journal: Addiction Date: 2010-03-10 Impact factor: 6.526
Authors: Shadi Nahvi; Alain H Litwin; Moonseong Heo; Karina M Berg; Xuan Li; Julia H Arnsten Journal: Drug Alcohol Depend Date: 2011-08-31 Impact factor: 4.492
Authors: Bach Xuan Tran; Arto Ohinmaa; Anh Thuy Duong; Nhan Thi Do; Long Thanh Nguyen; Quoc Cuong Nguyen; Steve Mills; Philip Jacobs; Stan Houston Journal: Qual Life Res Date: 2011-07-06 Impact factor: 4.147
Authors: Megha Ramaswamy; Patricia J Kelly; Xuan Li; Karina M Berg; Alain H Litwin; Julia H Arnsten Journal: J Assoc Nurses AIDS Care Date: 2012-08-04 Impact factor: 1.354